Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone

Inclusion Criteria: * The patient's age is ≥ 19 years old * Histologically or cytologically confirmed solid tumor * Patients diagnosed as malignancy who will be treated with highly emetogenic chemotherapeutic agents (NCCN guideline v2.0, 2014 anti-emesis). (Cisplatin dosage is over 50mg/m2, combination therapy is available with other chemotherapeutic agents and including lymphoma) * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Available oral administration of study drugs * Adequate organ functions as follows: 1) Hematologic - white blood cell count (WBC) ≥ 3000 microliter (microL) or Neutrophil≥ 1500 micro/L, Platelet ≥ 100,000/microL; 2) Serum Creatinine ≤ 1.5 times upper limit of normal; 3) Hepatic function - Total bilirubin, AST, ALT ≤2.5 times upper limit of normal, ALP ≤ 2 times upper limit of normal( except ALP increasing due to bone metastasis * Patients with normal range of serum K, Mg and hold serum Ca over lower limit of normal range * Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital Exclusion Criteria: * Patients with severe Hypertension, severe Heart disease, congenital long QT syndrome, bradyarrhythmia severe kidney disease(serum creatinine≥3㎎/㎗), liver disease (AST, ALT ≥ 2.5 times of upper normal range, ALP ≥ 2 times of upper normal range) * Patients with GI obstruction, active gastric ulcer or other diseases that could provoke nausea and vomiting * Patients who have nausea and vomiting within 1 week before chemotherapy * Patients who should take steroid, antiemetics, antipsychotic agent including benzodiazepine, pimozide, terfenadine, astemizole, cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir or nelfinavir, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors for the treatment of other diseases * Patients with brain tumor, brain metastasis or seizure * Patients receiving chemotherapy within 6 months before enrollment * Patients who need radiation therapy during study period or receiving radiation therapy within 2 weeks before chemotherapy * Patients who have known allergy or severe side effect on study drugs(5-HT3 antagonist and aprepitant) * Pregnant or lactating women, or women who wish to become pregnant * Patients with drug abuse, a mental disease and difficult to communicate with investigators * Others whom the investigator judges inappropriate as subjects for this study